Disease-modifying anti-asthmatic drugs

[1]  G. Koppelman,et al.  Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.

[2]  A. Sheikh,et al.  Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes , 2021, European Respiratory Journal.

[3]  I. Pavord,et al.  Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. , 2021, The Lancet. Respiratory medicine.

[4]  H. Kantarjian,et al.  Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion/TP53 mutations. , 2021, Blood.

[5]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[6]  J. Upham,et al.  Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.

[7]  J. Virchow,et al.  Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult‐onset than in severe early‐onset asthma , 2021, Allergy.

[8]  M. Humbert,et al.  Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) , 2021, European Respiratory Journal.

[9]  S. Vermeire,et al.  Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial , 2021, The Lancet.

[10]  P. O'Byrne,et al.  Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. , 2021, JAMA.

[11]  G. Canonica,et al.  One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. , 2021, The journal of allergy and clinical immunology. In practice.

[12]  S. Yancey,et al.  Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.

[13]  H. Hammad,et al.  The basic immunology of asthma , 2021, Cell.

[14]  S. Ng,et al.  Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD. , 2021, Gastroenterology.

[15]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[16]  E. Bel,et al.  Long-term therapy response to anti-interleukin-5 biologics in severe asthma - a real-life evaluation. , 2020, The journal of allergy and clinical immunology. In practice.

[17]  A. Chang,et al.  More options for managing severe asthma in adults. , 2020, The Lancet. Respiratory medicine.

[18]  I. Pavord,et al.  Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. , 2020, The Lancet. Respiratory medicine.

[19]  I. Pavord,et al.  Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial , 2020, The Lancet. Respiratory medicine.

[20]  R. Mosges,et al.  Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model , 2020, Allergy.

[21]  A. Douiri,et al.  Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[22]  Y. Gon,et al.  Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[23]  H. Kerstjens,et al.  Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[24]  M. Lommatzsch.  Immune Modulation in Asthma: Current Concepts and Future Strategies , 2020, Respiration.

[25]  C. Bachert,et al.  Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. , 2020, The Journal of allergy and clinical immunology.

[26]  J. Kavanagh,et al.  Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[27]  M. Dougados,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis , 2020, Annals of the Rheumatic Diseases.

[28]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[29]  I. Pavord,et al.  An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.

[30]  J. Virchow,et al.  Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.

[31]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[32]  C. Janson,et al.  Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden , 2019, Allergy.

[33]  A. Sheikh,et al.  GINA 2019: a fundamental change in asthma management , 2019, European Respiratory Journal.

[34]  H. Hammad,et al.  The Cytokines of Asthma. , 2019, Immunity.

[35]  I. Abraham,et al.  Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018 , 2019, Expert review of clinical immunology.

[36]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[37]  C. Brightling,et al.  Asthma , 2018, The Lancet.

[38]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[39]  S. Durham,et al.  Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. , 2017, The Journal of allergy and clinical immunology.

[40]  W. Busse,et al.  A randomized multicenter study evaluating Xolair persistence of response after long‐term therapy , 2017, The Journal of allergy and clinical immunology.

[41]  G. Burmester,et al.  Novel treatment strategies in rheumatoid arthritis , 2017, The Lancet.

[42]  G. Yancopoulos,et al.  Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[43]  D. Price,et al.  Managing asthma in the era of biological therapies. , 2017, The Lancet. Respiratory medicine.

[44]  J. Virchow,et al.  Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. , 2016, JAMA.

[45]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[46]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[47]  J. Drazen,et al.  A patient with asthma seeks medical advice in 1828, 1928, and 2012. , 2012, The New England journal of medicine.

[48]  A. James,et al.  Remission of asthma: The next therapeutic frontier? , 2011, Pharmacology & therapeutics.

[49]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[50]  G. Canonica,et al.  Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. , 2010, The Journal of allergy and clinical immunology.

[51]  R. Puy,et al.  Injection allergen immunotherapy for asthma. , 2010, The Cochrane database of systematic reviews.

[52]  S. Johnston,et al.  Mechanisms of adverse effects of β-agonists in asthma , 2009, Thorax.

[53]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[54]  R. Keren,et al.  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. , 2006, The Cochrane database of systematic reviews.

[55]  J Crane,et al.  End of the New Zealand asthma mortality epidemic , 1995, The Lancet.

[56]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[57]  C. Print,et al.  Regular inhaled beta-agonist treatment in bronchial asthma , 1990, The Lancet.

[58]  A M Adelstein,et al.  Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. , 1969, Lancet.

[59]  J. Howell,et al.  A double-blind trial of disodium cromoglycate in the treatment of allergic bronchial asthma. , 1967, Lancet.

[60]  J. H. Comroe,et al.  A method for the objective evaluation of bronchodilator drugs: effects of dapanone, isuprel, and aminophylline in patients with bronchial asthma. , 1955, The Journal of allergy.

[61]  A. Frankland,et al.  Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. , 1954, Lancet.

[62]  W. Burrage,et al.  The role of cortisone in the treatment of severe bronchial asthma. , 1953, The New England journal of medicine.

[63]  E. Schwartz.  Oral cortisone therapy in intractable bronchial asthma. , 1951, Journal of the American Medical Association.

[64]  W. Busse,et al.  The Relationship of Asthma Biologics to Remission for Asthma , 2022, The Journal of Allergy and Clinical Immunology: In Practice.